Zacks Research Weighs in on Chemours’ Q3 Earnings (NYSE:CC)

The Chemours Company (NYSE:CC) – Stock analysts at Zacks Research dropped their Q3 2026 earnings per share estimates for Chemours in a research note issued on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the specialty chemicals company will post earnings per share of $0.74 for the quarter, down from their previous estimate of $0.78. The consensus estimate for Chemours’ current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours’ Q4 2026 earnings at $0.45 EPS.

A number of other equities analysts have also issued reports on the stock. Barclays dropped their target price on shares of Chemours from $19.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 1st. Royal Bank of Canada decreased their price target on shares of Chemours from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Thursday, May 8th. Morgan Stanley cut their price objective on shares of Chemours from $22.00 to $15.00 and set an “equal weight” rating for the company in a research report on Monday, May 12th. The Goldman Sachs Group reduced their target price on shares of Chemours from $21.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 14th. Finally, BMO Capital Markets lowered their price target on Chemours from $34.00 to $27.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Chemours presently has an average rating of “Hold” and an average target price of $17.56.

Chemours Stock Down 5.4%

Shares of CC stock opened at $10.57 on Thursday. Chemours has a 12 month low of $9.33 and a 12 month high of $27.65. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The firm has a market cap of $1.58 billion, a PE ratio of 18.54 and a beta of 1.76. The stock has a 50 day moving average of $12.13 and a 200-day moving average of $16.15.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.06). The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.36 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. Chemours’s revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Strategic Financial Concepts LLC acquired a new stake in shares of Chemours during the 4th quarter worth about $357,000. Entropy Technologies LP acquired a new position in Chemours in the fourth quarter valued at about $266,000. Sei Investments Co. grew its stake in Chemours by 779.5% during the fourth quarter. Sei Investments Co. now owns 174,555 shares of the specialty chemicals company’s stock worth $2,950,000 after buying an additional 154,709 shares during the last quarter. Twelve Points Wealth Management LLC grew its stake in Chemours by 42.8% during the fourth quarter. Twelve Points Wealth Management LLC now owns 78,325 shares of the specialty chemicals company’s stock worth $1,324,000 after buying an additional 23,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Chemours during the fourth quarter worth approximately $515,000. 76.26% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO Shane Hostetter purchased 4,450 shares of the stock in a transaction on Monday, May 19th. The shares were purchased at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the completion of the transaction, the chief financial officer now directly owns 59,694 shares of the company’s stock, valued at approximately $673,348.32. The trade was a 8.06% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.47% of the company’s stock.

Chemours Announces Dividend

The firm also recently announced a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a yield of 3.17%. Chemours’s payout ratio is currently 175.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.